The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis

Clinical Endocrinology

Volumn 72, Issue 6, 2010, Pages 752-757

  Anastasilakis, Athanasios D ^a   Polyzos, Stergios A ^b   Avramidis, Avraam ^c   Toulis, Konstantinos A ^a   Papatheodorou, Athanasios ^d   Terpos, Evangelos ^d  

^a 424 General Army Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Aristotle University of Thessaloniki   (Greece)

^d 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DICKKOPF 1 PROTEIN; PARATHYROID HORMONE[1-34]; VITAMIN D; WNT PROTEIN; BONE DENSITY CONSERVATION AGENT; DKK1 PROTEIN, HUMAN; PARATHYROID HORMONE; SIGNAL PEPTIDE;

AGED; ARTICLE; BLOOD ANALYSIS; BONE DENSITY; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; LUMBAR VERTEBRA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; TERIPARATIDE;

EID: 77952615076     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03728.x     Document Type: Article

References (38)

1. Sambrook, P. Cooper, C. (2006) Osteoporosis. Lancet, 367, 2010 2018.
2. Amantea, C.M., Kim, W.K., Meliton, V. et al. (2008) Oxysterol-induced osteogenic differentiation of marrow stromal cells is regulated by Dkk-1 inhibitable and PI3-kinase mediated signaling. Journal of Cellular Biochemistry, 105, 424 436.
3. Hodsman, A.B., Bauer, D.C., Dempster, D.W. et al. (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrine Reviews, 26, 688 703.
4. Body, J.J., Gaich, G.A., Scheele, W.H. et al. (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology and Metabolism, 87, 4528 4535.
5. Withold, W., Schulte, U. Reinauer, H. (1996) Method for determination of bone alkaline phosphatase activity;analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Clinical Chemistry, 42, 210 217.
6. Neer, R.M., Arnaud, C.D., Zanchetta, J.R. et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 344, 1434 1441.
7. Dobnig, H., Sipos, A., Jiang, Y. et al. (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. Journal of Clinical Endocrinology and Metabolism, 90, 3970 3977. (Pubitemid 41058159)
8. Delmas, P.D., Licata, A.A., Reginster, J.Y. et al. (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone, 39, 237 243.
9. Anastasilakis, A.D., Goulis, D.G., Polyzos, S.A. et al. (2008) Head-to-head comparison of risedronate versus teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomized trial. International Journal of Clinical Practice, 62, 919 924.
10. Canalis, E., Economides, A.N. Gazzerro, E. (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocrine Reviews, 24, 218 235.
11. Gregory, C.A., Gunn, W.G., Reyes, E. et al. (2005) How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Annals of New York Academy Science, 1049, 97 106.
12. Canalis, E., Giustina, A. Bilezikian, J.P. (2007) Mechanisms of anabolic therapies for osteoporosis. New England Journal of Medicine, 357, 905 916.
13. Rawadi, G., Vayssière, B., Dunn, F. et al. (2003) BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. Journal of Bone and Mineral Research, 18, 1842 1853.
14. Sheikh, S.S., Mbalaviele, G., Warlow, P. et al. (2001) Beta-catenin signaling during osteoblast differentiation. Journal of Bone and Mineral Research, 16, S368.
15. Qiang, Y.W., Barlogie, B., Rudikoff, S. et al. (2008) Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone, 42, 669 680.
16. van der Horst, G., van der Werf, S.M., Farih-Sips, H. et al. (2005) Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. Journal of Bone and Mineral Research, 20, 1867 1877.
17. Fujita, K. Janz, S. (2007) Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Molecular Cancer, 6, 71.
18. Lane, N.E., Nevitt, M.C., Lui, L.Y. et al. (2007) Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheumatism, 56, 3319 3325.
19. Lee, N., Smolarz, A.J., Olson, S. et al. (2007) A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. British Journal of Cancer, 97, 1552 1559.
20. Kaiser, M., Mieth, M., Liebisch, P. et al. (2008) Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. European Journal of Haematology, 80, 490 494.
21. Voorzanger-Rousselot, N., Goehrig, D., Journe, F. et al. (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. British Journal of Cancer, 97, 964 970.
22. Voorzanger-Rousselot, N., Journe, F., Doriath, V. et al. (2009) Assessment of circulating dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases. Calcified Tissue International, 84, 348 354.
23. Voskaridou, E., Christoulas, D., Xirakia, C. et al. (2009) Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica, 94, 725 728.
24. Anastasilakis, A.D., Polyzos, S.A., Goulis, D.G. et al. (2008) Endogenous intact PTH is suppressed during teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis. Endocrine Journal, 55, 613 616.
25. Krishnan, V., Bryant, H.U. Macdougald, O.A. (2006) Regulation of bone mass by Wnt signaling. Journal of Clinical Investigation, 116, 1202 1209.
26. Suzuki, A., Ozono, K., Kubota, T. et al. (2008) PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. Journal of Cellular Biochemistry, 104, 304 317.
27. Wang, F.S., Ko, J.Y., Yeh, D.W. et al. (2008) Modulation of dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology, 149, 1793 1801.
28. Wang, F.S., Ko, J.Y., Lin, C.L. et al. (2007) Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone, 40, 485 492.
29. Terpos, E., Dimopoulos, M.A. Sezer, O. (2007) The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia, 21, 1875 1884.
30. Schwaninger, R., Rentsch, C.A., Wetterwald, A. et al. (2007) Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. American Journal of Pathology, 170, 160 175.
31. Zegels, B., Eastell, R., Russell, R.G. et al. (2001) Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. Bone, 28, 108 112.
32. Keller, H. Kneissel, M. (2005) SOST is a target gene for PTH in bone. Bone, 37, 148 158.
33. Bellido, T., Ali, A.A., Gubrij, I. et al. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology, 146, 4577 4583.
34. Bodine, P.V., Seestaller-Wehr, L., Kharode, Y.P. et al. (2007) Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. Journal of Cellular Physiology, 210, 352 357.
35. Qin, L., Qiu, P., Wang, L. et al. (2003) Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. Journal of Biological Chemistry, 278, 19723 19731.
36. van Bezooijen, R.L., Svensson, J.P., Eefting, D. et al. (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. Journal of Bone and Mineral Research, 22, 19 28.
37. Anastasilakis, A.D., Goulis, D.G., Polyzos, S.A. et al. (2008) Acute changes in serum osteoprotegerin and Receptor Activator for Nuclear Factor κB ligand levels in women with established osteoporosis treated with teriparatide. European Journal of Endocrinology, 158, 411 415.
38. Aguilera, O., Peña, C., García, J.M. et al. (2007) The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis, 28, 1877 1884.